Drug Dealers | search
Click here to view Drug Dealers news from 60+ newspapers.
Bookmark or Share- Deals - BioPharma DiveSarepta rebuilds drug pipeline with Arrowhead deal A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.
- Monte Rosa joins with Novartis in ‘molecular glue’ drug dealNovartis’ deal with Monte Rosa centers on an early-stage drug candidate dubbed MRT-6160 that’s currently in a Phase 1 study of healthy volunteers. Monte Rosa and Novartis see potential for MRT-6160 to treat “multiple” systemic and neurological autoimmune diseases, Monte Rosa CEO Markus Warmuth said in an email to BioPharma Dive.
- The golden era of GLP-1 drugs: Where we are and what comes nextDrug developers are also investigating the potential for longer-lasting injections. Oral formulations are another future enhancement for GLP-1 RA medicines, with several pill forms in development. Various physiological barriers, such as mucus, intestinal, and enzymatic barriers, interfere with the oral delivery or absorption of protein and ...
- Sarepta rebuilds drug pipeline with Arrowhead dealSarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four clinical-stage treatments and three others still in preclinical testing. In return, Sarepta will pay Arrowhead $ ...
- Metsera touts long-acting GLP-1 drug; Novartis strikes an AI dealObesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097, that’s designed to have longer-lasting effects than injectable GLP-1 therapies like Novo Nordisk’s Wegovy. The results show that a weekly ...
More
